Publications and Presentations

Please note that the safety and efficacy of the agents discussed herein are under investigation and have not been established.

May 11, 2024

A Phase 2, Randomized, Double-Blind, Placebo- Controlled Study to A ssess the Tolerability and Pharmacodynamic Effects of CRD-740, a PDE9 Inhibitor, in Participants with Chronic Heart Failure

The CARDINAL-HF Trial

Oral presentation at the Annual Congress of the Heart Failure Association of the European Society of Cardiology 2024

James Udelson, Jan Bělohlávek, Andrej Dukát, Justin Ezekowitz, Sorel Goland, Bela Merkerly, Eileen O’Meara, Mark Petrie, Piotr Ponikowski, Michele Senni, Mariya Tokmakova, Orly Vardeny, Howard Surks, Scott Solomon, John McMurray

November 12, 2023

Novel, Potent, and Highly Selective Calcium/calmodulin-Dependent Protein Kinase II (CaMKII) Inhibitors Reduce Substrate Phosphorylation in Rat Hearts and Prolong Survival in a Mouse Model of Severe Heart Failure

Oral presentation at the American Heart Association Scientific Sessions 2023.

Focus: CaMKII, Heart failure

Shuichi Takagahara, Mioko Harada, Mari Asada, Masataka Harada, Masao Hirakata, Howard K. Surks, Michael E. Mendelsohn and Shota Ikeda